Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.
about
Acute Myeloid Leukemia: A Concise ReviewMonitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesMolecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceNovel therapeutic options in Acute Myeloid LeukemiaNovel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaRecurrent CDC25C mutations drive malignant transformation in FPD/AML.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?High-throughput monitoring of integration site clonality in preclinical and clinical gene therapy studies.Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.Leukemia diagnosis: today and tomorrow.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.Diagnostic work-up of acute myeloid leukemia.Minimal residual disease in acute myelogenous leukemia.Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse.Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing.Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing.Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes.Emerging molecular predictive and prognostic factors in acute myeloid leukemia.Methods of Detection of Measurable Residual Disease in AML.Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies.Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN.Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS eraRare Event Detection Using Error-corrected DNA and RNA Sequencing
P2860
Q26766719-14BF3EE4-A4E1-4C51-AD68-A49C3779D1DCQ26770394-487EF840-6F5B-4659-856B-28319005DD19Q26776393-1A15A28A-FFB0-4680-B357-40FEC02FD050Q28069889-B314BAED-6398-4C00-BCE3-FDC754303C97Q28075654-C4622F97-ADF9-4B1D-B350-9B9A7C02D237Q33417335-B123C56D-CB0C-445B-96FD-501A1E3894ADQ33832709-51192910-98E7-47E1-A8E0-64AFC1CA4E8EQ33840223-40AEA0D1-034B-4003-80C6-7FBB4DD266C3Q35665038-17C7C478-06EF-4026-8A53-E06F5264BF77Q35992927-2E7D8454-81DA-42BE-B436-BAE792CE39E4Q36849666-B2C5664C-341B-4D89-913B-B1AC5EAA77DCQ37624593-BFC9AC9E-C791-48DC-A54E-B60D3B3C304BQ38154339-CC5B9ADE-EED9-41D2-AE35-EA2FCE126536Q38537725-BA23A40A-3894-4A0E-82BD-183B2AA91AF6Q38672646-FFBCE826-FCB0-486F-8211-01AA9F2BE247Q38755213-2B453B65-E140-43D2-90AE-7BFD01CD88C3Q38902497-8A14CFED-D365-477A-B0F3-A187729C6947Q38904250-67DA7D13-B01B-4324-ADCC-C3F212C0D6E7Q39076258-8D1A3E9D-4641-4AA6-B321-2FC50C2144F0Q39266354-41E72079-01AA-4F34-99D5-2C330B6C9895Q39285841-EA47827B-F2ED-4A0D-B7B2-2CF3CDF4E825Q40497621-7B980DB1-8FE8-4875-A502-E8EDAC50AF97Q41674738-0190A333-02AF-457C-A626-94A7B22B8232Q41885481-A1FB7F4C-1BEA-45A6-945A-560CF958E327Q42322251-6CAA974B-47C9-4B8D-A826-EAD95BAD61B2Q42337304-2788515C-E82C-4D45-8C1B-DE35FC7D488EQ47109503-DABF3C24-D03D-4A3F-87F9-CE4A95B06FE3Q47670541-5724731C-56B2-4847-ADD6-59DC8EC533E7Q47862030-990F8AC6-A49A-47DD-A89F-0E473B43B7EEQ48272510-2669DAEA-F5AA-4386-BB1A-689D784A300CQ50642627-0DC9CBD7-6C4A-4405-BF06-EAEAEE258A49Q53479508-B66C8821-2148-432E-8029-36FA172D7477Q54256273-7348D79A-8681-4EF0-B575-F750AE959228Q58734773-C5E393E6-1EC7-4686-AC36-0B13F2FE3BEDQ58800914-4E167148-3AF2-47A3-80C9-840408C76D19
P2860
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Monitoring of residual disease ...... tients with resistant disease.
@en
Monitoring of residual disease ...... tients with resistant disease.
@nl
type
label
Monitoring of residual disease ...... tients with resistant disease.
@en
Monitoring of residual disease ...... tients with resistant disease.
@nl
prefLabel
Monitoring of residual disease ...... tients with resistant disease.
@en
Monitoring of residual disease ...... tients with resistant disease.
@nl
P2093
P2860
P356
P1433
P1476
Monitoring of residual disease ...... tients with resistant disease.
@en
P2093
A Kohlmann
N Nadarajah
S Schindela
S Schnittger
T Alpermann
V Grossmann
P2860
P2888
P304
P356
10.1038/LEU.2013.239
P577
2013-08-20T00:00:00Z